Bleakley Financial Group LLC Acquires 30,702 Shares of Kenvue Inc. $KVUE

Bleakley Financial Group LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 11.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 309,109 shares of the company’s stock after purchasing an additional 30,702 shares during the quarter. Bleakley Financial Group LLC’s holdings in Kenvue were worth $5,329,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Physician Wealth Advisors Inc. grew its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Elyxium Wealth LLC bought a new position in shares of Kenvue during the fourth quarter valued at $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue in the 4th quarter worth about $28,000. Reflection Asset Management bought a new stake in shares of Kenvue in the 4th quarter worth about $32,000. Finally, SBI Securities Co. Ltd. increased its position in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 2.4%

Shares of NYSE:KVUE opened at $18.76 on Wednesday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The company’s 50-day moving average price is $18.12 and its two-hundred day moving average price is $17.82. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The firm has a market cap of $36.02 billion, a P/E ratio of 22.07, a P/E/G ratio of 1.46 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the previous year, the firm posted $0.24 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.59% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen raised shares of Kenvue to a “buy” rating in a research note on Sunday. UBS Group dropped their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Citigroup cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Finally, Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.